Corvus Pharmaceuticals (CRVS) Operating Expenses (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Operating Expenses of $14.9 million for Q1 2026, up 49.94% year-over-year from $9.9 million in Q1 2025, and up 40.72% quarter-over-quarter from $10.6 million in Q3 2025.
Corvus Pharmaceuticals (CRVS) Operating Expenses (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Operating Expenses history runs 12 years deep, the most recent figure standing at $14.9 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 49.94% year-over-year to $14.9 million; the TTM figure through Mar 2026 stood at $35.7 million (up 54.5% YoY), while the FY2023 annual figure was $23.4 million, down 28.12% from the prior year.
- Operating Expenses for Q1 2026 stood at $14.9 million, up from $10.6 million in the prior quarter.
- The five-year high for Operating Expenses was $14.9 million in Q1 2026, with the low at $5.6 million in Q3 2023.
- The 5-year median for Operating Expenses is $7.0 million (2022), against an average of $8.1 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses slumped 55.42% in 2023, then surged 72.87% in 2025.
- Corvus Pharmaceuticals' Operating Expenses stood at $5.7 million in 2022, then fell by 0.26% to $5.7 million in 2023, then rose by 28.38% to $7.3 million in 2024, then jumped by 45.72% to $10.6 million in 2025, then jumped by 40.72% to $14.9 million in 2026.
- Business Quant data shows CRVS's Operating Expenses at $14.9 million in Q1 2026, $10.6 million in Q3 2025, and $10.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Corvus Pharmaceuticals | 1.25 Bn | 1.04 Bn | - | 19.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.30 Mn |
| Mar 31, 2026 | 14.88 Mn |
| Sep 30, 2025 | 10.57 Mn |
| Jun 30, 2025 | 10.26 Mn |
| Mar 31, 2025 | 9.92 Mn |
| Sep 30, 2024 | 7.26 Mn |
| Jun 30, 2024 | 5.94 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | 5.62 Mn |
| Mar 31, 2023 | 6.57 Mn |
| Dec 31, 2022 | 5.67 Mn |
| Sep 30, 2022 | 12.47 Mn |
| Jun 30, 2022 | 7.01 Mn |
| Mar 31, 2022 | 7.41 Mn |
| Dec 31, 2021 | 6.81 Mn |
| Sep 30, 2021 | 9.05 Mn |
| Jun 30, 2021 | 11.29 Mn |
| Mar 31, 2021 | 11.48 Mn |